Athanassios Argiris Selected Research

Gefitinib (Iressa)

4/2013	Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
2/2010	Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
1/2006	Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
6/2004	Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
3/2004	Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Athanassios Argiris Research Topics

Disease

43	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021 - 05/2002
42	Neoplasms (Cancer) 03/2022 - 11/2002
33	Squamous Cell Carcinoma of Head and Neck 03/2022 - 07/2006
17	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 03/2004
10	Disease Progression 01/2022 - 12/2003
7	Lung Neoplasms (Lung Cancer) 01/2021 - 06/2004
5	Neoplasm Metastasis (Metastasis) 01/2021 - 12/2003
4	Neutropenia 12/2019 - 08/2004
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2011 - 02/2004
3	Fatigue 12/2020 - 12/2010
3	Thrombocytopenia (Thrombopenia) 12/2019 - 08/2004
3	Diarrhea 04/2013 - 03/2004
3	Mucositis 01/2010 - 08/2004
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2008 - 05/2005
2	Pain (Aches) 12/2020 - 01/2017
2	Hyponatremia 12/2019 - 12/2016
2	Headache (Headaches) 12/2016 - 08/2012
2	Anemia 12/2016 - 12/2003
2	Complementation Group E Xeroderma Pigmentosum 10/2011 - 12/2010
2	Colorectal Neoplasms (Colorectal Cancer) 02/2010 - 08/2004
2	Carcinoma (Carcinomatosis) 07/2007 - 11/2004
1	Necrosis 01/2022
1	Nasopharyngeal Carcinoma 01/2022
1	Residual Neoplasm 01/2022
1	Hemorrhage 12/2019
1	Peripheral Nervous System Diseases (PNS Diseases) 12/2019
1	Febrile Neutropenia 12/2019
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2019
1	Edema (Dropsy) 12/2016
1	Oropharyngeal Neoplasms 01/2016

Drug/Important Bio-Agent (IBA)

15	ErbB Receptors (EGF Receptor)IBA 10/2018 - 03/2004
13	Cetuximab (Erbitux)FDA Link 10/2018 - 07/2007
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2006
9	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2017 - 06/2004
9	Docetaxel (Taxotere)FDA Link 11/2015 - 11/2002
9	Cisplatin (Platino)FDA LinkGeneric 10/2014 - 11/2002
7	Paclitaxel (Taxol)FDA LinkGeneric 12/2019 - 05/2004
7	Tyrosine Kinase InhibitorsIBA 04/2013 - 03/2004
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 10/2009
5	Bevacizumab (Avastin)FDA Link 01/2020 - 02/2010
5	Gefitinib (Iressa)FDA Link 04/2013 - 03/2004
5	Proteins (Proteins, Gene)FDA Link 04/2012 - 06/2004
4	Monoclonal AntibodiesIBA 12/2019 - 07/2007
4	PlatinumIBA 12/2019 - 08/2011
4	Carboplatin (JM8)FDA LinkGeneric 12/2019 - 03/2008
4	Fluorouracil (Carac)FDA LinkGeneric 01/2017 - 05/2004
4	Irinotecan (Camptosar)FDA LinkGeneric 07/2013 - 11/2002
4	Bortezomib (Velcade)FDA Link 07/2013 - 01/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 08/2011
3	LigandsIBA 01/2019 - 02/2010
3	Pemetrexed (MTA)FDA Link 06/2013 - 08/2004
3	Epidermal Growth Factor (EGF)IBA 11/2012 - 06/2004
3	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2011 - 12/2003
3	Hydroxyurea (Hydrea)FDA LinkGeneric 08/2004 - 01/2003
2	Tadalafil (Cialis)FDA Link 03/2022 - 01/2020
2	NivolumabIBA 03/2022 - 01/2020
2	Immune Checkpoint InhibitorsIBA 03/2022 - 01/2019
2	Programmed Cell Death 1 ReceptorIBA 06/2021 - 01/2019
2	veliparibIBA 01/2021 - 12/2019
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 12/2019
2	Antisense DNAIBA 10/2018 - 03/2009
2	Everolimus FDA Link 12/2016 - 12/2010
2	Pharmaceutical PreparationsIBA 12/2016 - 05/2016
2	TOR Serine-Threonine KinasesIBA 12/2016 - 12/2010
2	Sulindac (Copal)FDA LinkGeneric 06/2014 - 11/2012
2	Proteasome InhibitorsIBA 07/2013 - 01/2011
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 10/2009 - 04/2008
2	Celecoxib (Celebrex)FDA Link 04/2008 - 05/2006
2	Gemcitabine FDA Link 03/2005 - 08/2004
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 03/2022
1	Angiogenesis InhibitorsIBA 01/2022
1	apatinibIBA 01/2022
1	thiamine triphosphorate (TTP)IBA 12/2020
1	antineoplaston A10 (A 10)IBA 01/2020
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2019
1	Cytotoxins (Cytolysins)IBA 12/2019
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 08/2017
1	rilotumumabIBA 08/2017
1	CrizotinibIBA 01/2017
1	PerforinIBA 01/2017
1	Granzymes (Granzyme)IBA 01/2017
1	human ALK1-Fc fusion proteinIBA 12/2016
1	Activin Receptors (Activin Receptor)IBA 12/2016
1	AntibodiesIBA 01/2016
1	Protein Subunit VaccinesIBA 05/2014
1	VaccinesIBA 05/2014
1	Neoplasm Antigens (Tumor Antigens)IBA 05/2014
1	Etoposide (VP 16)FDA LinkGeneric 10/2013
1	Histone Deacetylase InhibitorsIBA 10/2013
1	PanobinostatIBA 10/2013

Therapy/Procedure

28	Therapeutics 02/2022 - 05/2002
24	Drug Therapy (Chemotherapy) 01/2021 - 05/2002
21	Radiotherapy 01/2022 - 01/2003
10	Chemoradiotherapy 01/2021 - 05/2002
6	Immunotherapy 02/2022 - 01/2017
6	Induction Chemotherapy 10/2013 - 12/2003
3	Neck Dissection (Radical Neck Dissection) 12/2007 - 05/2004
2	Combined Modality Therapy 01/2021 - 05/2004
1	Laryngectomy 01/2019
1	Injections 10/2018